share_log

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

Benzinga ·  Apr 3 20:18
Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment